TriSalus Life Sciences announced it has requested a drawdown of $10 million under its previously established $50 million credit agreement with OrbiMed. This additional funding became available to TriSalus upon achieving a product revenue-based milestone of $30 million for the trailing 12-months ending January 31, 2025.
With the closing of this $10 million tranche, the company has now drawn a total of $35 million under the credit agreement with OrbiMed. This capital infusion strengthens the company's financial position and provides resources to support its ongoing growth strategies.
The successful drawdown demonstrates the company's ability to meet its revenue targets and access committed financing, which is crucial for funding investments in commercial expansion and new Pressure-Enabled Drug Delivery (PEDD) applications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.